What is Supernus Pharmaceuticals's total revenue?

Supernus Pharmaceuticals (SUPN) reported total revenue of $207.71M in Q1 2026.

How has Supernus Pharmaceuticals's total revenue changed year-over-year?

Supernus Pharmaceuticals's total revenue increased by 38.6% year-over-year, from $149.82M to $207.71M.

What is the long-term trend for Supernus Pharmaceuticals's total revenue?

Over 4 years (2021 to 2025), Supernus Pharmaceuticals's total revenue has grown at a 5.5% compound annual growth rate (CAGR), from $579.78M to $718.95M.

What does total revenue mean?

The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.

Supernus Pharmaceuticals SUPN Total Revenue

Total Revenue at other companies

AbbVieABBV

$15B+12.4%

Catalyst PharmaceuticalCPRX

$149.39M+5.6%

Axsome TherapeuticsAXSM

$191.2M+57.4%

Neurocrine BiosciencesNBIX

$814.5M+42.2%

Jazz PharmaceuticalsJAZZ

$1.07B+19.1%

Acadia PharmaceuticalsACAD

$268.06M+9.7%

Segments

By product

See full

Qelbree$77.84M+20.2%

GOCOVRI$35.24M+14.8%

Royalty, licensing, and other revenues$29.31M+274%

Collaboration revenue (ZURZUVAE)$27.64M—

Trokendi XR$9.48M-26.0%

ONAPGO$8.38M—

By segment

See full

Reportable Segment$207.71M+38.6%

Other financials

Income statement

See full

Gross profit$184.3M+37.5%

Operating income-$8.3M+18.8%

Net income-$2.3M+80.6%

EPS (diluted)-$0.04+81.0%

Balance sheet

See full

Cash & equivalents$186.3M+60.8%

Total debt$40.9M+26.6%

Total equity$1.1B+4.5%

Total assets$1.5B+11.4%

Cash flow

See full

Operating cash flow$66.5M+117%

CapEx--100%

Free cash flow$66.5M+120%

Valuation

See full

Market cap$2.58B+62.8%

Enterprise value$2.44B+62.3%

P/S3.3×+0.9×

Profitability

See full

Gross margin89.4%+1.0pp

Operating margin-7.8%-18.9pp

Net margin-3.7%-13.0pp

FCF margin27.9%+3.4pp

Returns & leverage

See full

Return on equity-2.8%-9.1pp

Debt / equity0×0.0×

Current ratio2×-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Supernus Pharmaceuticals's total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Supernus Pharmaceuticals's total revenue?: Supernus Pharmaceuticals (SUPN) reported total revenue of $207.71M in Q1 2026.
How has Supernus Pharmaceuticals's total revenue changed year-over-year?: Supernus Pharmaceuticals's total revenue increased by 38.6% year-over-year, from $149.82M to $207.71M.
What is the long-term trend for Supernus Pharmaceuticals's total revenue?: Over 4 years (2021 to 2025), Supernus Pharmaceuticals's total revenue has grown at a 5.5% compound annual growth rate (CAGR), from $579.78M to $718.95M.
What does total revenue mean?: The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.